Kling Bio Joins Forces with Sanofi to Identify Neutralizing Antibodies

Shots:Kling Bio has entered into a collaboration & license option agreement with Sanofi to discover antibodies & epitopes leveraging Kling Bio’s Kling-Select platformCollaboration aims to discover & characterize monoclonal antibodies with strong neutralizing activity against human viral pathogen to allow development of novel antiviral therapiesKling-Select is a validated B cell immortalization platform…

ByRidhi RastogiJuly 24, 2025

NEWS

GSK Reports the US FDA’s Approval of Nucala (Mepolizumab) for Chronic Obstructive Pulmonary Disease (COPD)

Shots:The US FDA has approved Nucala as an add-on treatment for inadequately controlled COPD & eosinophilic phenotype based on the P-III (MATINEE & METREX) trial; EMA & NMPA’s submissions are under reviewMATINEE assessed Nucala (n=403; 100mg, SC, Q4W) vs PBO (n=401) in COPD pts (n=804) with type 2 inflammation while METREX evaluated it…

ByRidhi RastogiMay 23, 2025

VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots: Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…

BySaurabh ChaubeyNovember 4, 2024

INSIGHTS+

Disease of the Month- Osteoporosis

To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Continuing the series for the disease of the month, PharmaShots brings a condensed report on Osteoporosis, a bone and tissue disorder October 20th is observed as…

BySenior EditorOctober 12, 2023

TOP 20

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Shots:Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and researchIn 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…

ByPrince GiriSeptember 26, 2023

THOUGHTSPOT

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

Technologies and innovations have transformed the world globally. Traveling to different places, interacting with new people, working remotely from home, and much more comes with evolving technologies. With all these bright perspectives, it’s also an indisputable fact that we are now more susceptible to diseases than we were a few decades ago. After the outbreak…

BySaurabh ChaubeyFebruary 20, 2023

Kling Bio Joins Forces with Sanofi to Identify Neutralizing Antibodies

GSK Reports the US FDA’s Approval of Nucala (Mepolizumab) for Chronic Obstructive Pulmonary Disease (COPD)

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Disease of the Month- Osteoporosis

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

Contact US

OUR INFORMATION

FOLLOW US